TY - JOUR
T1 - Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy
T2 - A retrospective multicenter analysis (KROG 1418)
AU - Kim, Yeon Joo
AU - Park, Won
AU - Ha, Boram
AU - Park, Boram
AU - Joo, Jungnam
AU - Kim, Tae Hyun
AU - Park, In Hae
AU - Lee, Keun Seok
AU - Lee, Eun Sook
AU - Shin, Kyung Hwan
AU - Kim, Haeyoung
AU - Yu, Jeong Il
AU - Choi, Doo Ho
AU - Huh, Seung Jae
AU - Wee, Chan Woo
AU - Kim, Kyubo
AU - Park, Kyung Ran
AU - Kim, Yong Bae
AU - Ahn, Sung Ja
AU - Lee, Jong Hoon
AU - Kim, Jin Hee
AU - Chun, Mison
AU - Lee, Hyung Sik
AU - Kim, Jung Soo
AU - Cha, Jihye
N1 - Publisher Copyright:
© 2017 by the Korean Cancer Association.
PY - 2017
Y1 - 2017
N2 - Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
AB - Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
UR - http://www.scopus.com/inward/record.url?scp=85030762872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030762872&partnerID=8YFLogxK
U2 - 10.4143/crt.2016.508
DO - 10.4143/crt.2016.508
M3 - Article
C2 - 28052654
AN - SCOPUS:85030762872
SN - 1598-2998
VL - 49
SP - 927
EP - 936
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 4
ER -
